{
    "2019-12-03": [
        [
            {
                "time": "2018-12-03",
                "original_text": "小米斥资约1.69亿港元回购1878.2万股",
                "features": {
                    "keywords": [
                        "小米",
                        "回购",
                        "港元"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "新城发展前11个月销售额升24.17%至2465.62亿元 复星医药：阿莫西林胶囊通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "新城发展",
                        "销售额",
                        "复星医药",
                        "阿莫西林胶囊",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "房地产",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "A股头条之上市公司",
                "features": {
                    "keywords": [
                        "A股",
                        "上市公司"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "复星国际控股增持复星医药40.5万股 每股作价22.0057港元",
                "features": {
                    "keywords": [
                        "复星国际",
                        "增持",
                        "复星医药",
                        "港元"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "以药品集中采购和使用为突破口，医药领域供给侧改革按下“快进键”",
                "features": {
                    "keywords": [
                        "药品集中采购",
                        "供给侧改革",
                        "医药领域"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "复星医药附属阿莫西林胶囊通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "复星医药",
                        "阿莫西林胶囊",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-02",
                "original_text": "智通港股通持股分析",
                "features": {
                    "keywords": [
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "智通港股股东权益披露",
                "features": {
                    "keywords": [
                        "港股",
                        "股东权益"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "一纸公告山水再现 —— 海普瑞的跨国运营地图",
                "features": {
                    "keywords": [
                        "海普瑞",
                        "跨国运营"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}